The TORTUGA trial tested filgotinib, a JAK1 inhibitor, in active ankylosing spondylitis (AS) patients and was shown to be both effective and capable of retarding sacroiliac (SI) joint erosions as early as 12 weeks. https://t.co/awfZdiTUBt https://t.co/ST2JIkavhy